Substituted heterocyclic compounds for treating multidrug resistance

• US 7,135,483 B2
• Filed: 11/29/2001
• Issued: 11/14/2006
• Est. Priority Date: 10/17/2000
• Status: Expired due to Term

• Current Assignee: H Lee Moffitt Cancer Center & Research Institute (State University System of Florida)
• Original Assignee: H Lee Moffitt Cancer Center & Research Institute (State University System of Florida)
• Inventors: Degenhardt, Charles Raymond, Eickhoff, David Joseph
• Primary Examiner(s): DESAI, RITA J
• Application Number:
  US09/996,657
• Publication Number:
  US 20020099215A1
• Time in Patent Office: 1,811 Days
• Field of Search: 546/192, 546/223, 546/225, 546/229, 514/329, 514/330, 514/331
• US Class Current: 514/324
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/48 Preparations in capsules, e.g. of gelatin, of chocolate A61K9/0004 takes precedence; bite capsules A61K9/0056
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 211/27 having amino groups linked to the six-membered aromatic ring by saturated carbon chains
• CPC Class Codes: C07C 237/06 having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• CPC Class Codes: C07C 237/24 having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
• CPC Class Codes: C07C 2601/14 The ring being saturated
• CPC Class Codes: C07C 271/22 to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• CPC Class Codes: C07C 51/06 from carboxylic acid amides
• CPC Class Codes: C07C 57/38 polycyclic
• CPC Class Codes: C07D 207/16 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 211/58 attached in position 4
• CPC Class Codes: C07D 211/60 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 211/62 attached in position 4
• CPC Class Codes: C07D 213/30 Oxygen atoms
• CPC Class Codes: C07D 213/56 Amides
• CPC Class Codes: C07D 213/78 Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 215/20 Oxygen atoms
• CPC Class Codes: C07D 215/233 only one oxygen atom which is attached in position 4
• CPC Class Codes: C07D 239/06 : having one double bond between ring members or between a ring member and a non-ring member
• CPC Class Codes: C07D 263/06 : with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
• CPC Class Codes: C07D 263/12 : with radicals containing only hydrogen and carbon atoms
• CPC Class Codes: C07D 295/15 : to an acyclic saturated chain
• CPC Class Codes: C07D 295/205 : Radicals derived from carbonic acid
• CPC Class Codes: C07D 401/02 : containing two hetero rings
• CPC Class Codes: C07D 401/06 : linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/12 : linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 : containing three or more hetero rings
• CPC Class Codes: C07D 405/12 : linked by a chain containing hetero atoms as chain links

Abstract

Substituted heterocyclinc compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted heterocyclic compound has the formula:

Claims

1. A compound having the structure;

2. The compound according to claim 1 wherein x is 1.

3. The compound according to claim 1 wherein x is 0.

4. The compound according to claim 1 wherein t is 0 to 2.

5. The compound according to claim 1 wherein R⁶ is a substituted aromatic group.

6. A composition comprising:

(a) the compound according to claim 1; and

(b) a pharmaceutically acceptable carrier.